CD8A and Epstein-Barr virus infection: These observations and accumulating evidence from adoptive immunotherapy studies suggest that an ideal vaccine should prevent acute symptoms of primary EBV infection through the induction of robust humoral and cellular immunity including neutralizing antibodies and EBV-specific CD4+ and CD8+ T cell responses.